

Recombinant Production of *E. coli* NAD⁺-dependent DNA ligase as a Target for Antibacterial Drug Discovery

Özlem KAPLAN¹^{ℓℓ}, Rizvan İMAMOĞLU², İsa GÖKÇE³

¹Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, 34134, Vezneciler, İstanbul, Turkey, ²Department of Molecular Biology and Genetics, Faculty of Science, Bartin University, Turkey, ³Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Tokat Gaziosmanpaşa University, Turkey

¹https://orcid.org/0000-0002-3052-4556, ²https://orcid.org/0000-0002-6306-4760, ³https://orcid.org/0000-0002-5023-9947

ABSTRACT

The increase in the frequency of drug resistance in bacterial infections has led to the research of new antibacterial agents targeting new mechanisms. Many of the functions of NAD⁺-dependent DNA ligase have made it a remarkable target for antibacterial drug discovery. *Escherichia coli* (*E. coli*) NAD⁺-dependent DNA ligase is presented as a potential target due to its unique substrate specificity compared to the ATP-dependent human DNA ligase. In this study, it was aimed to produce and purify the *E. coli* NAD + dependent DNA ligase enzyme, which is frequently used in antibacterial drug discovery. *The E. coli* DNA ligase gene sequence was cloned into pTOLT vector system. *E. coli* DNA ligase enzyme was purified after the production in *E. coli BL21 (DE3) pLysE* cells. It was clearly demonstrated by the activity test that the DNA ligase enzyme produced in this study can ligate the DNA fragments. As a result, it was revealed that the effect of candidate inhibitors can be studied simply on the enzyme.

Research Article

Article History Geliş Tarihi ÷ 21.02.2021 Kabul Tarihi ÷ 20.04.2021

Keywords

NAD⁺⁻dependent DNA ligase TolAIII peptide Antibacterial Drug Discovery

Antibakteriyel İlaç Keşfi İçin Bir Hedef Olarak *E. Coli* NAD+Bağımlı DNA Ligazın Rekombinant Üretimi

ÖZET

Bakteriyel enfeksiyonlarda ilaç direnci frekansındaki artış, yeni mekanizmaları hedefleyen yeni antibakteriyel ajanların NAD+-bağımlı araştırılmasına yol açmıştır. DNA ligazın fonksiyonlarının bir çoğu, onu antibakteriyel ilaç keşfi için dikkate değer bir hedef haline getirmiştir. Escherichia coli (E. coli) NAD+ bağımlı DNA ligazı, ATP bağımlı insan DNA ligazı ile karşılaştrıldığında, benzersiz substrat özgüllüğü nedeniyle potansiyel bir hedef olarak görülmektedir. Bu çalışmada antibakteriyel ilaç keşiflerinde sıklıkla kullanılan E. coli NAD+ bağımlı DNA ligaz enziminin, yüksek miktarda ve saflıkta üretilmesi amaçlamıştır. E. coli DNA ligaz gen dizisi, pTOLT vektör sistemine klonlanmıştır. E. coli DNA ligaz enzimi, E. coli BL21 (DE3) pLysE hücrelerinde üretildikten sonra saflaştırılmıştır. Bu çalışmada üretilen DNA ligaz enziminin DNA fragmanlarının ligasyonunu sağlayabildiği, aktivite testi ile açıkça gösterilmiştir. Sonuç olarak, bu enzim üzerinde aday inhibitörlerin etkisinin basitçe incelenebileceği ortaya koyulmuştur.

Araştırma Makalesi

Makale TarihçesiReceived: 21.02.2021Accepted: 20.04.2021

Anahtar Kelimeler NAD+-bağımlı DNA ligaz TolAIII peptid Antibakteriyel İlaç Keşfi

To Cite :Kaplan Ö, İmamoğlu R, Gökçe İ 2022. Recombinant Production of *E. coli* NAD+-dependent DNA ligase as a Target
for Antibacterial Drug Discovery. KSU J. Agric Nat 25 (1): 19-24. https://doi.org/10.18016/ksutarimdoga.vi.
884279

INTRODUCTION

DNA ligase is important in DNA repair and replication (Cardona-Felix et al. 2010). DNA synthesis in one strand may be continuous in DNA replication, while synthesis is not continuous in the other strand. DNA ligase is crucial for joining Okazaki fragments and fulfilling DNA synthesis (Timson et al. 2000). Nicks caused by environmental factors such as radiation, oxidants and alkylating agents which are repaired by the activity of the DNA ligase (Crut et al. 2008). DNA ligase is an essential protector of genome integrity (Odell et al. 2000). Various organisms such as *E. coli* (Wilkinson et al. 2005), *Mycobacterium tuberculosis* (*M. tuberculosis*) (Srivastava et al. 2007),

Staphylococcus aureus (S. aureus) (Kaczmarek et al. 2001) have NAD⁺-dependent DNA ligase. T7bacteriophage, Haemophilus influenzae (H. influenzae) (Doherty et al. 1996), Staphylothermus marinus (S. marinus) (Seo et al. 2007) have ATPdependent DNA ligase. In addition, all known eukaryotic DNA ligases are ATP dependent (Wilkinson et al. 2001). Bacterial genomes sequenced so far contain at least one NAD+-dependent DNA ligase. NAD⁺-dependent ligase has been cloned from various bacterial sources and sequenced. These sequences appear to be significantly similar and all have almost the same size (75 kDa) (Timson et al. 2000). These enzymes have two functional domains: the C terminal domain is the domain of binding to DNA. It is seen that a zinc ion is bound in the C terminal domain of these enzymes. The N terminal domain is responsible for the self-adenylating reaction and NAD⁺ binding (Wilkinson et al. 2001). The DNA sequence of the DNA ligase gene of a wide range of bacterial species (Jonsson et al. 1994; Lauer et al. 1991; Subramanya et al. 1996; Timson et al. 2000) has been identified, and some conserved regions have been determined and compared with the discovery regions in E. coli. Alignment of amino acid sequences displays that S. aureus NAD⁺⁻dependent DNA ligase has 47% and 60% amino acid identity with E. coli and Bacillus stearothermophilus NAD+-dependent DNA ligase, respectively. It has been displayed in further studies that these DNA ligases have motifs preserved in other bacteria (Kaczmarek et al. 2001).

E. coli DNA is a protein encoded by the LigA gene, the enzyme has 671 amino acids and its molecular weight is 73,690 kDa. Wilkinson et al. (2005) found that *E. coli* LigA protein has contains zinc-finger, oligomerbinding (OB) h-barrel, helix-hairpin-helix motif (HhH) and BRCT domain. In the same study, *E. coli* LigA gene was cloned into the pET16b vector. The vector contains a 10-His-Tag containing 21 extra amino acids at the N-terminal of protein. Also, it was stated that the presence of His-Tag at the N-terminal or C-terminal end did not affect enzyme activity (Wilkinson et al. 2005).

NAD⁺-dependent DNA ligases are considered to be possible targets for broad spectrum antibacterial compounds (Gong et al. 2004; Kaczmarek et al. 2001; Lee et al. 2000; Sriskanda and Shuman 2002; Swift and Amaro 2009), because they are unavoidable for many basic processes of DNA metabolism, including replication, recombination processes and repairs that require re-synthesis of DNA connection of Okazaki fragments in the pathway (Timson et al. 2000). The ligase inhibitors developed are generally competitive inhibitors and can bind to hydrophobic pockets near the NAD⁺ substrate binding site (Swift and Amaro 2009). They inhibit the LigA activity of *Streptococcus pneumoniae* (*S. pneumoniae*), *H. influenzae, E. coli*, *Mycoplasma* and *S. aureus.* Their inhibitory activities are very high (in the nanomolar range) and are selective for bacterial DNA ligase (Mills et al. 2011). There are several studies in the literature on the inhibition of *E. coli* DNA LigA. Gong et al. found that pyropyranone compounds strongly inhibited the ligation activity of *E. coli* DNA LigA (IC₅₀ = 0.6 μ M) (Gong et al. 2004). Dwivedi et al. have demonstrated that Quinacrine (9-aminoacidine) is a strong candidate for inhibition of *E. coli* DNA LigA (Dwivedi et al. 2008). Mills et al. have described several adenosine analogs as inhibitors of LigA. These compounds have been shown to be effective in *H. influenzae* as well as *E. coli* DNA LigA (Alomari 2019; Mills et al. 2011).

In this study, *E. coli* NAD+-dependent DNA ligase enzyme, which is frequently used in antibacterial drug discoveries, was aimed at high level production and purification. First, the *E. coli* DNA ligase gene was cloned into the pTOLT vector system and then expressed in *E. coli BL21 (DE3) pLysE* cells. The enzyme was purified by affinity chromatography and its activity was demonstrated.

MATERIALS and METHOD

Cloning of the *E. coli* DNA Ligase Gene into the pTOLT Vector System

The gene was first amplified for cloning the *E. coli* DNA Ligase gene into the pTOLT vector (Anderluh et al. 2003). PCR (polymerase chain reaction) mixture was prepared using primers of *ligABamHI*sense 5'TTTTGGATCCATGGAATCAATCGAACAAC3' and *ligAKpnI*reverse 5'TTTTGGTACCGCTACCCAGCAA ACGCAG3'.

After PCR reaction, 10 μ l of PCR mixture was taken and analyzed in 1% agarose gel. The obtained PCR products were purified with the PCR products cleaning kit and digested with *BamHI* and *KpnI* restriction enzymes. The pTOLT plasmid which was used for cloning was also cut with the same restriction enzymes. *E. coli* DNA Ligase gene and pTOLT plasmid digestion by restriction enzymes were ligated with T4 DNA ligase enzyme at room temperature for 16 hours. The ligation products were transferred to *E. coli* DH5a cells and spread on ampicillin (100 μ g ml⁻¹) containing LB medium. Plasmid DNA was isolated from the colonies, and diagnostic restriction digest and diagnostic PCR were performed on plasmids. The obtained products were analyzed in 1% agarose gel.

Expression of *E. coli* DNA Ligase Protein

Protein expression and purification was carried out similar to the protocol detailed in our previous work (Kuduğ et al. 2019; Kaplan et al. 2021). In summary, for protein expression, pTOLT clones were transformed into *E. coli* BL21 (DE3) pLysE and spread on LB medium containing ampicillin (100 µg ml⁻¹). After overnight incubation, the colonies were transferred to the 4 mL LB liquid medium containing antibiotics. Then the cells were inoculated instead of 600 mL antibiotic LB liquid medium and protein expression was induced by IPTG when OD600: 0.7. The cells were collected by centrifugation 4 hours after induction and lysed by sonicator. The lysate was centrifuged, supernatant was taken and proteins were purified by affinity chromatography (Ni-NTA Agarose Resin). Each fraction taken from the column was analyzed in SDS-PAGE.

Activity Test of E. coli DNA Ligase enzyme

The pET28b vector was digested for 3 hours with BamHI and ApaI enzyme. After 3 hours, it was purified with the "Biobasic Gel and PCR Clean-Up" kit. The digested and purified pET28b vector was ligated with different amounts of *E. coli* DNA ligase enzyme elutions for 2 hours at 25°C.

RESULTS and DISCUSSION

Cloning of the *E. coli* DNA Ligase Gene into the pTOLT Vector System

As a result of the PCR reaction, it was observed in the 1% agarose gel that the *E. coli* DNA ligase gene (LigA) was amplified in the 2016 bp size (Figure 1).



- Figure 1. Analysis of the colony PCR results in 1% agarose gel. Column 1 is λ DNA/EcoRI/ HindIII Marker, Columns 3-6 is 2016 bp PCR product.
- Şekil 1. Koloni PCR sonuçlarının %1 agaroz jelde analizi. Sütun 1, λDNA/EcoRI/ HindIII markeridir, Sütun 3-6, 2016 bç PCR ürünüdür.

Confirmation of cloning was performed by diagnostic restriction digestion using *MluI* and *XhoI* restriction enzymes. As seen in Figure 2, it is revealed with the presence of the *E. coli* Lig A gene region around 2016 bp and the pTOLT vector around 4300 bp.

Diagnostic PCR was also performed with *ligABamHI*sense and *ligAKpnI*reverse primers using plasmid DNAs that were found to be positive in the diagnostic restriction digestion process (Figure 3).



- Figure 2. Analysis of the diagnostic digestion results in 1% agarose gel. Column 1 is \DNA/EcoRI/Hind III Marker, Columns 4 and 7 are plasmids containing the *E. coli* LigA gene, and columns 2, 3, 5, 6, 8 are plasmids that do not contain the *E. coli* LigA gene.
- Şekil 2. Doğrulama kesim sonuçlarının %1 agaroz jelde analizi. Sütun 1, λDNA/EcoRI/ HindIII markeridir, Sütun 4 ve 7, E. coli LigA genini içeren plazmitlerdir ve sütun 2, 3, 5, 6, 8, E. coli LigA genini içermeyen plazmitlerdir.



- Figure 3 Analysis of diagnostic PCR results in 1% agarose gel. Column 1 is λ DNA/EcoRI/HindIII Marker and columns 4, 5 are PCR products.
- Şekil 3. Doğrulama PCR sonuçlarının %1 agaroz jelde analizi. Sütun 1, λDNA/EcoRI/ HindIII markeridir ve 4. 5. sütunlar PCR ürünleridir.

As a result of diagnostic PCR and diagnostic restriction analysis, *E. coli* LigA gene has been successfully cloned into pTOLT vector and, the pTOL-*E. coli* DNA Ligase plasmid was obtained (Figure 4).

Expression of *E. coli* DNA Ligase Protein

The pTOLT plasmid has a DNA sequence encoding the TolAIII peptide of 9 kDa as fusion. TolAIII is a small domain, expressed in high yields of soluble proteins in the cytoplasm of *E. coli*. The *E. coli* DNA ligase enzyme is 74 kDa in size and appears to be 83 kDa with the 9 kDa TolAIII peptide in SDS-PAGE gel (Figure 5).



Figure 4. Plasmid map of pTOL-*E. coli* DNA Ligase construct to produce TolAIII and *E. coli* DNA Ligase fusion *Şekil 4. TolAIII ve E. coli DNA Ligaz füzyonunu oluşturan pTOL-E.coli DNA Ligaz'ın plazmid haritası*



- Figure 5. Analysis of the purified *E. coli* DNA Ligase protein in 12% SDS-PAGE gel. 1. Page Ruler Plus Prestained Protein Ladder 2. *E. coli BL21 (DE3) pLysE* cell lysates before IPTG addition, 3. *E. coli BL21 (DE3) pLysE* cell lysates after IPTG addition, 4-8. purified Tol-III-A-DNA Ligase fusion protein.
- Şekil 5. Saflaştırılan E. coli DNA Ligaz poteininin % 12 SDS-PAGE jelinde analizi. 1. Page Ruler Plus Prestained Protein Ladder 2. IPTG ilavesinden önce E. coli BL21 (DE3) pLysE hücre lizatları, 3. IPTG ilavesinden sonra E. coli BL21 (DE3) pLysE hücre lizatları, 4-8. saflaştırılmış Tol-III-A-DNA Ligaz füzyon proteini.

The protein obtained in column 4 is> 95% purity. Protein concentration was determined as 2 mg ml⁻¹ by the Bradford method.

Activity Test of E. coli DNA Ligase enzyme

The activity test was performed by taking different concentrations of *E. coli* DNA ligase enzyme purified by affinity chromatography. As a negative control, an Enzyme-free sample and a sample containing elution $(1 \ \mu)$ from *E. coli BL21 (DE3) pLysE* cells without plasmid were used. As a positive control, T4 DNA

Ligase enzyme was used (Figure 6). It was clearly seen that the DNA ligase enzyme produced in this study ligated the DNA fragments. These results reveal that the effect of inhibitors on *E. coli* DNA ligase enzyme can be demonstrated simply in agarose gel electrophoresis.



- Figure 6. Analysis of the activity test of the purified protein in 1% agarose gel. 1. Enzyme-free sample. 2. Sample containing elution (1 µl) from *E. coli BL21* (*DE3*) *pLysE* cells without plasmid. 3. Sample containing T4 DNA Ligase enzyme (1 µl). 4. ADNA/EcoRI/HindIII Marker. 5, 6, 7 are samples containing 1, 2, 3 µl of *E. coli* DNA Ligase elution, respectively.
- Şekil 6. Saflaştırılan proteinin aktivite testinin % 1 agaroz jelde analizi 1. Enzim içermeyen numune. 2. Plazmid içermeyen E. coli BL21 (DE3) pLysE hücrelerinden elde edilen elüsyonu içeren örnek (1 ul). 3. T4 DNA Ligaz enzimi (1 μl) içeren örnek. 4. λDNA /EcoRI/HindIII Marker. 5, 6, 7 sırasıyla 1, 2, 3 μl E. coli DNA Ligaz elüsyonu içeren örneklerdir.

CONCLUSION

DNA ligase plays an important role in DNA recombination, replication, and repair of all living organisms. The bacterial NAD⁺-dependent DNA ligase

(LigA) has high potential as a broad spectrum antibacterial target. Bacterial NAD⁺-dependent DNA ligase is essential for the viability of all Gram-positive and Gram-negative bacteria tested so far, including *S. aureus, S. pneumoniae, Escherichia coli, Salmonella typhimurium, Bacillus subtilis, Salmonella enteritidis* (Dermody et al. 1979; Kaczmarek et al. 2001; Meier et al. 2008; Shuman 2009). NAD⁺-dependent DNA ligases were not detected in humans, which led to the research that it could be the target for broad-spectrum antibiotics (Brotz-Oesterhelt et al. 2003;

Georlette et al. 2003; Gong et al. 2004; Kaczmarek et al. 2001; Lee et al. 2000; Sriskanda and Shuman (2002) spectrum antibiotics (Brotz-Oesterhelt et al. 2003; Georlette et al. 2003; Gong et al. 2004; Kaczmarek et al. 2001; Lee et al. 2000; Sriskanda and Shuman 2002). NAD⁺-dependent DNA Ligases have low similarity with eukaryotic DNA ligase, and the need for NAD⁺ as a substrate for ligase activity makes the bacterial ligase unique, thus limiting toxicity for humans (Korycka-Machala et al. 2007). Ligases are found in all three systems of life (bacteria, archaea and eukaryotes), while NAD⁺-dependent enzymes are only present in bacteria (Wilkinson et al. 2001). At least one NAD+-dependent DNA ligase is found in each bacterium. Genetic studies have demonstrated that the LigA gene is required for *E. coli* growth (Shuman 2009). NAD+-dependent ligase (LigA) is an essential enzyme for the survival of *E. coli* and its homologous protein may be required for all bacteria (Wilkinson et al. 2001).

In this study, the *E. coli* DNA ligase gene fragment was cloned into the pTOLT vector system. The protein expression was performed in *E. coli BL21 (DE3) pLysE* cells and the protein was purified. The E. coli DNA ligase protein was highly expressed by fusion with the TolAIII peptide. The greatest advantage of expression in combination with TolAIII is that it provides high efficiency protein production in *E. coli* (Anderluh et al. 2003). The TolAIII peptide significantly increased the production of *E. coli* DNA ligase protein. The activity of the purified protein was confirmed by an activity test. It has been revealed that the effect of selected inhibitors can be studied simply on the enzyme we produce within the scope of this study. In addition, the produced *E. coli* DNA ligase enzyme can also be used in molecular cloning processes.

ACKNOWLEDGEMENT

This study was supported by the Turkish Scientific and Technical Research Council (TUBITAK) (TUBITAK-2209A)

Researchers Contribution Rate Declaration Summary The authors declare that they have contributed equally to the article.

Conflicts of Interest Statement

Authors have declared no conflict of interest.

REFERENCES

- Alomari A, Allen, M 2019. Clone, purify and 1D Nuclear Magnetic Resonance Spectroscopy of the BRCT Domain of E. coli DNA Ligase LigA. Iraqi Journal of Biotechnologies 18: 2.
- Anderluh G, Gokce I, Lakey JH 2003. Expression of proteins using the third domain of the Escherichia coli periplasmic-protein TolA as a fusion partner. Protein Expr Purif 28: 173-181. doi:10.1016/s1046-5928(02)00681-2.
- Brotz-Oesterhelt H, Knezevic I, Bartel S, Lampe T, Warnecke-Eberz U, Ziegelbauer K, Habich D, Labischinski H 2003. Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochroma nones. J Biol Chem 278:39435-39442. doi:10.1074/ jbc.M306479200.
- Cardona-Felix CS, Pastor-Palacios G, Cardenas H, Azuara-Liceaga E, Brieba LG 2010. Biochemical characterization of the DNA ligase I from Entamoeba histolytica. Mol Biochem Parasitol 174: 26-35. doi:10.1016/j.molbiopara.2010.06.010.
- Crut A, Nair PA, Koster DA, Shuman S, Dekker NH 2008. Dynamics of phosphodiester synthesis by DNA ligase. Proc Natl Acad Sci U S A 105:6894-6899. doi:10.1073/pnas.0800113105.
- Dermody JJ, Robinson GT, Sternglanz R 1979. Conditional-lethal deoxyribonucleic acid ligase mutant of Escherichia coli. J Bacteriol 139:701-704.
- Doherty AJ, Ashford SR, Wigley DB 1996. Characterization of proteolytic fragments of bacteriophage T7 DNA ligase. Nucleic Acids Res 24:2281-2287. doi:10.1093/nar/24.12.2281.
- Dwivedi N, Dube D, Pandey J, Singh B, Kukshal V, Ramachandran R, Tripathi RP (2008) NAD(+)dependent DNA ligase: a novel target waiting for the right inhibitor. Med Res Rev 28:545-568. doi:10.1002/med.20114.
- Georlette D, Blaise V, Dohmen C, Bouillenne F, Damien B, Depiereux E., Gerday C, Uversky VN, Feller G 2003. Cofactor binding modulates the conformational stabilities and unfolding patterns of NAD(+)-dependent DNA ligases from Escherichia coli and Thermus scotoductus. J Biol Chem 278:49945-49953. doi:10.1074/jbc.M307761200.
- Gong C, Martins A, Bongiorno P, Glickman M, Shuman S 2004. Biochemical and genetic analysis of the four DNA ligases of mycobacteria. J Biol Chem 279: 20594-606. doi:10.1074/jbc.M401841200
- Jonsson ZO, Thorbjarnardottir SH, Eggertsson G, Palsdottir A 1994. Sequence of the DNA ligaseencoding gene from Thermus scotoductus and conserved motifs in DNA ligases. Gene 151: 177-180. doi:10.1016/0378-1119(94)90652-1.
- Kaczmarek FS, Zaniewski RP, Gootz TD, Danley DE, Mansour MN, Griffor M, Kamath AV, Cronan M,

Mueller J, Sun D, Martin PK, Benton B, McDowell L, Biek D, Schmid MB 2001. Cloning and functional characterization of an NAD(+)-dependent DNA ligase from Staphylococcus aureus. J Bacteriol 183: 3016-3024. doi:10.1128/JB.183.10.3016-3024. 2001.

- Kaplan Ö, İmamoğlu R, Şahingöz İ, Gökçe İ 2021. Recombinant production of Thermus aquaticus single-strand binding protein for usage as PCR enhancer. International Advanced Researches and Engineering Journal. 5(1): 42-46. doi:10.35860/ iarej.766741.
- Korycka-Machala M, Rychta E, Brzostek A, Sayer HR, Rumijowska-Galewicz A, Bowater RP, Dziadek J 2007. Evaluation of NAD(+) -dependent DNA ligase of mycobacteria as a potential target for antibiotics. Antimicrob Agents Chemother 51:2888-2897. doi:10.1128/AAC.00254-07.
- Kuduğ H, Ataman B, İmamoğlu R, Düzgün D, Gökçe İ 2019. Production of red fluorescent protein (mCherry) in an inducible E. coli expression system in a bioreactor, purification and characterization. International Advanced Researches and Engineering Journal. 3(1): 20-25.
- Lauer G, Rudd EA, McKay DL, Ally A, Ally D, Backman KC 1991. Cloning, nucleotide sequence, and engineered expression of Thermus thermophilus DNA ligase, a homolog of Escherichia coli DNA ligase. J Bacteriol 173: 5047-5053. doi:10.1128/jb.173.16.5047-5053.1991.
- Lee JY, Chang C, Song HK, Moon J, Yang JK, Kim HK, Kwon ST, Suh SW 2000. Crystal structure of NAD(+)- dependent DNA ligase: modular architecture and functional implications. EMBO J 19: 1119-1129. doi:10.1093/emboj/19.5.1119.
- Meier TI, Yan D, Peery RB, McAllister KA, Zook C, Peng SB, Zhao G 2008. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases. FEBS J 275:5258-5271. doi:10.1111/j.1742-4658.2008.06652.x.
- Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS 2011. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. Antimicrob Agents Chemother 55:1088-1096. doi:10.1128/AAC.01181-10.

- Odell M, Sriskanda V, Shuman S, Nikolov DB 2000. Crystal structure of eukaryotic DNA ligaseadenylate illuminates the mechanism of nick sensing and strand joining. Mol Cell 6:1183-1193. doi:10.1016/s1097-2765(00)00115-5.
- Seo MS, Kim YJ, Choi JJ, Lee MS, Kim JH, Lee JH, Kwon ST 2007. Cloning and expression of a DNA ligase from the hyperthermophilic archaeon Staphylothermus marinus and properties of the enzyme. J Biotechnol 128:519-530. doi:10.1016/j. jbiotec.2006.09.024.
- Shuman S 2009. DNA ligases: progress and prospects. J Biol Chem 284:17365-17369. doi:10.1074/jbc. R900017200.
- Sriskanda V, Shuman S 2002. Conserved residues in domain Ia are required for the reaction of Escherichia coli DNA ligase with NAD+. J Biol Chem 277:9695-9700. doi:10.1074/jbc.M111164200.
- Srivastava SK, Dube D, Kukshal V, Jha AK, Hajela K, Ramachandran R 2007. NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor. Proteins 69:97-111.doi:10.1002/prot.21457.
- Subramanya HS, Doherty AJ, Ashford SR, Wigley DB 1996. Crystal structure of an ATP-dependent DNA ligase from bacteriophage T7. Cell 85:607-615. doi:10.1016/s0092-8674(00)81260-x.
- Swift RV, Amaro RE 2009. Discovery and design of DNA and RNA ligase inhibitors in infectious microorganisms. Expert Opin Drug Discov 4:1281-1294. doi:10.1517/17460440903373617.
- Timson DJ, Singleton MR, Wigley DB 2000. DNA ligases in the repair and replication of DNA. Mutat Res 460: 301-318. doi:10.1016/s0921-8777(00) 00033 -1.
- Wilkinson A, Day J, Bowater R 2001. Bacterial DNA ligases. Mol Microbiol 40: 1241-1248. doi:10.1046/ j.1365-2958.2001.02479.x.
- Wilkinson A, Smith A, Bullard D, Lavesa-Curto M, Sayer H, Bonner A, Hemmings A, Bowater R 2005. Analysis of ligation and DNA binding by Escherichia coli DNA ligase (LigA). Biochim Biophys Acta 1749: 113-122. doi:10.1016/j.bbapap. 2005.03.003.